Fecal Microbiota Transfer (FMT) is a procedure that has shown strong effectiveness in treating C.Difficile. Researchers are also exploring FMT’s role for treating other diseases, such as IBD and multidrug-resistant bacteria. This interactive workshop will give you the opportunity to learn from two highly experienced clinicians and a leading European Biotech who will address the important considerations in FMT that must be evaluated for global adoption.
The session will be split into three therapeutic applications of FMT:
Emilie Plantamura, Clinical Project Manager, MaaT Pharma
Harry Sokol, Professor of Gastroenterology, Assistance Publique-Hopitaux De Paris
While the number of published microbiome studies continues to rise at an exponential rate, few are well designed, adequately powered, and incorporate systems biology. Without a true systems approach, it is certainly difficult to make sense of much of the microbiome data, much less rest on such data for expensive product development decisions. Furthermore, potential breakthrough microbiome therapies face serious translational hurdles if the key efficacy data arises solely from animal models. Thus, the industry needs to break old paradigms and re-write the rule books in order to succeed.
Executives of all types (science, business, regulatory) who are involved in a microbiome development program must consider four core strategic questions:
This interactive workshop will give you the opportunity to engage with three highly experienced microbiome specialists who visualise the microbiome from different perspectives. Will next-gen probiotics be the best solution? Will pharmaceutical drugs supplant consumer products? Short term versus long term?If we were to rewrite all the rules, what would this look like?
Larry Weiss, CMO, AOBiome
Johan Vlieg, VP, Microbiome and Human Health Innovation, Chr. Hansen
Mohan Iyer, Chief Business Officer, Second Genome, Inc.